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Abstract
Post-streptococcal autoimmunity affects millions worldwide, targeting multiple organs including the heart, brain, and
kidneys. To explore the post-streptococcal autoimmunity spectrum, we used western blot analyses, to screen 310 sera from
healthy subjects with (33%) and without (67%) markers of recent streptococcal infections [anti-Streptolysin O (ASLO) or anti-
DNAse B (ADB)]. A 58 KDa protein, reacting strongly with post-streptococcal sera, was identified as Protein Disulfide
Isomerase (PDI), an abundant protein with pleiotropic metabolic, immunologic, and thrombotic effects. Anti-PDI
autoantibodies, purified from human sera, targeted similar epitopes in Streptolysin O (SLO, P51-61) and PDI (P328-338). The
correlation between post-streptococcal status and anti-human PDI auto-immunity was further confirmed in a total of 2987
samples (13.6% in 530 ASLO positive versus 5.6% in 2457 ASLO negative samples, p,0.0001). Finally, anti-PDI auto-
antibodies inhibited PDI-mediated insulin degradation in vitro (n=90, p,0.001), and correlated with higher serum insulin
(14.1 iu/ml vs. 12.2 iu/ml, n=1215, p=0.039) and insulin resistance (Homeostatic Model Assessment (HOMA) 4.1 vs. 3.1,
n=1215, p=0.004), in a population-based cohort. These results identify PDI as a major target of post-streptococcal
autoimmunity, and establish a new link between infection, autoimmunity, and metabolic disturbances.
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Introduction
Beta hemolytic streptococcal infections, typically pharyngitis
and skin infections, are usually benign, but can lead to serious
autoimmune complications such as rheumatic heart disease,
Sydenham chorea, and glomerulonephritis [1]. In rheumatic
heart disease, probably the most recognized post-streptococcal
autoimmune disease, molecular mimicry between streptococcal
antigens and selected cardiac proteins, triggers cardiac inflam-
mation, with resulting valvular damage [2,3]. The full extent of
post-streptococcal autoimmunity is still unclear and new post-
streptococcal entities have been suggested, notably encephalitis
lethargica [4], obsessive-compulsive disorder, and tics [5,6]. In
a recent study, we found a positive correlation between the
onset of narcolepsy and the levels of post-streptococcal
antibodies [7]. This led us to search for novel post-streptococcal
autoantibodies.
Protein Disulfide Isomerase (PDI) is a multifunctional enzyme
that primarily catalyzes disulfide bond formation, breakage, and
rearrangement [8]. Disulfide bonds stabilize the structure of
proteins and can regulate the activity of various enzymes [9] (Fig.
S1). PDI is primarily associated with the endoplasmic reticulum
(ER) where it participates in protein folding during biosynthesis.
It is also found on the cell membrane and may be actively
secreted by various cell types [9,10]. Extracellular PDI has been
shown to regulate a number of activities including: cellular
adhesion [11], pathogen entry (notably HIV) [12,13], platelet
aggregation and secretion [14], tissue factor pro-coagulant
activity (the limiting step in activation of the coagulation cascade)
[15,16,17,18], intracellular nitric oxide delivery [19], and insulin
degradation [20,21].
Insulin resistance is rapidly growing in frequency in association
with obesity in the developed world [22], and is a core
component of metabolic syndrome and diabetes (type 2).
Typically, high insulin levels are maintained in the face of high
plasma glucose, due to the reduced effects of insulin on fat, liver,
and muscle cells. Insulin resistance stimulates triglyceride
degradation and increases plasma levels of free fatty acids, while
also reducing glucose uptake and glycogen synthesis in the liver
and muscle.
Based on the relationship between PDI expression and insulin
degradation, we tested the hypothesis that streptococcal infections
and the resulting anti-PDI autoantibodies could have deleterious
effects on insulin metabolism.
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PDI is a major target of post-streptococcal autoimmunity
Three hundred and ten healthy participants, (‘‘Stanford
exploratory sample’’), were screened for the presence of
antistreptococcal antibodies, ASLO and ADB. Sixty-five subjects
(21%) had ASLO $200 IU, 67 (22%) had ADB $340 IU and a
total of 102 (33%) had ASLO $200 IU and/or ADB $340 IU
(‘‘post-streptococcal sera’’). These sera, diluted 1:250, were next
tested for the presence of autoantibodies on western blots of rat
colon, liver, intestine, urinary bladder, brain cortex, and brain-
stem extracts. We found that post-streptococcal sera reacted ,6
times more frequently than control sera with a 58 KDa protein
(Figure 1A), present in all tested tissues with highest affinity in the
colon, liver, and urinary bladder (26.4% versus 4.3% of control
sera in colon, n=310, p,0.0001). Following two-dimensional gel
separation, the 58 KDa protein was identified by mass spec-
trometry (MS) as PDI in liver, colon, and pancreas extracts (data
not shown). This was confirmed using purified bovine PDI
(Figure 1B- panels 1, 2) and recombinant human PDI (Figure 1C).
We next developed an ELISA assay using extracted bovine PDI
(1.5 mg/ml bovine PDI, 1:250 serum dilutions), and used this to
test sera from the initial 310 samples, an additional 372 subjects
(‘‘Stanford replication sample’’), and 1211 participants (2847
sera) of the Wisconsin Sleep Cohort. In all cases, ASLO or ADB
positive cases were more likely to be anti-bovine PDI positive
(Table 1). The odds ratio (OR) across all cohorts was 4.2 (95%CI:
3.5, 5.2).
Mimicry between PDI and Streptolysin-O (SLO)
A bovine PDI affinity column was next used to isolate anti-PDI
antibodies from human sera. These purified human autoantibod-
ies were then tested for cross-reactivity with Streptococcal proteins
(extracted from S. pyogenes). Strong reactivity was observed with a
69 KDa streptococcal protein present in the secreted fraction
(Figure 1B- panel 3), a protein later identified as Streptolysin O
(SLO) using Mass Spectrometry. Competitive ELISA demonstrat-
ed a specific and dose dependent inhibition of PDI binding, after
preincubation of anti-PDI positive sera with traces of purified SLO
(Figure 2A, ED50,10 ng), indicating that SLO specifically cross-
reacts with anti-PDI antibodies.
Importantly however, most ASLO positive sera were not anti-
PDI positive. Further, affinity purified anti-Streptolysin O
antibodies isolated from ASLO positive/anti-PDI negative sera
did not cross-react with PDI (Figure 2B). These results indicate
that ASLO antibody testing recognizes several types of antibodies,
targeting different SLO epitopes, with only a subset cross-reacting
with PDI. Computerized 3-D modeling of SLO and PDI identified
an eleven amino acid determinant, similar in SLO (p51-61) and
PDI (bovine: p330-340; human: p328-338), and exposed to solvent
in both proteins (Figures 2C, 2D). Interestingly, one lysine (K) of
the bovine/rat PDI (and SLO), is replaced by an arginine (R) in
humans (Figure 2C). We found that this change is associated with
a reduced affinity of the antibody for human PDI (as indicated by
higher serum concentrations needed to detect binding of the
antibody to recombinant human PDI -see methods). Nonetheless,
the 11-aminoacid determinant of bovine or human PDI,
Figure 1. PDI is a target of post-streptococcal autoimmunity. Proteins of various sources (described below) were separated by SDS-PAGE,
transferred to membranes, and probed with serum, total IgG, or affinity-purified antibodies extracted from participants. (A) Association of ASLO status
with auto-immunoreactivity, as detected by a 58 KDa immunoreactive band. Rat urinary bladder extracts (15 mg/strip) were probed with selected
ASLO positive ($400IU; lanes 1–4, 6 and 8) and negative (,100IU; lanes 5 and 7) sera. In this example 4 of 6 ASLO positive sera are also positive for
the 58 KDa band. (B) Reactivity of antibodies with: rat tissue extracts, extracted bovine PDI, streptococcus proteins and purified SLO. Lane 1- rat colon
extract (30 mg); lane 2 - purified bovine PDI (100 ng); lane 3 - Streptococcus pyogenes – secreted proteins (1.5 mg) and lane 4 – purified Streptolysin O
(10 ng). Proteins were immunobloted with: (1) total IgG from subject 2 (Figure 1A); (2) total IgG from anti-PDI negative/ASLO positive subject; (3)
affinity purified anti-PDI from subject 6 (Figure 1A) and (4) total IgG from rabbit immuned against bovine PDI -as control. (C) Reactivity of sera and
extracted anti-PDI autoantibodies with recombinant human PDI. Recombinant human PDI (1 mg/lane) was immunobloted against total IgG from
rabbit immuned against bovine PDI (lane 1); total IgG from subject 6 (lane 2); total IgG from subject 3 (lane 3); affinity purified anti-PDI from subject6
(lane 4) and affinity purified anti-SLO antibodies (lane 5).
doi:10.1371/journal.pone.0012875.g001
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competitive ELISAs (Fig. S2 A). Further analysis of anti-human
PDI antibodies suggest the existence of other determinants in
addition to the 11 amino acids region mentioned above (Fig. S2).
In addition to the observed association between ASLO and anti-
bovine PDI reactivity, strong association between anti-human PDI
and ASLO is present (Table 1, see also Table S1). The OR for
increased presence of anti-human PDI autoantibodies in conjunc-
tion with ASLO across all cohorts was 2.7 (95% CI: 2.0, 3.6).
Post-streptococcal anti-PDI antibodies inhibit PDI activity
Anti-PDI antibodies, induced by immunization of animals with
purified PDI, were shown recently to inhibit PDI function (in vitro
and in vivo) in leukocyte adhesion [11], viral entry [23], platelet
aggregation [24], tissue factor activation [16,17,18], and insulin
degradation [20]. To explore the putative functional effects of the
post-streptococcal anti-PDI antibodies identified in this study on
PDI activity, we used the insulin turbidity assay. This well-
established assay measures the activity of PDI using insulin as a
Table 1. Association between Anti-Streptolysin O (ASLO) and anti-PDI Antibodies.
ASLO
positive
$ ASLO negative
Odds Ratio
(95% CI) P value
Anti-bovine PDI
"
Exploratory sample (Stanford) 33.8% (65) 14.7% (245) 3.0 (1.6, 5.5) ,0.0001
Replication (Stanford) 33.3% (99) 11.4% (273) 3.9 (2.2, 6.8) ,0.0001
Wisconsin Sleep Cohort 38.6% (446) 10.2% (2401) 4.6 (3.7, 5.8) ,0.0001
All samples 37.2% (610) 12.2% (2919) 4.2 (3.5, 5.2) ,0.0001
Anti- human PDI
#
Exploratory sample (Stanford) 8.3% (24) 7.5% (80) 1.1 (0.2, 5.8) 0.92
Replication (Stanford) 5.9% (85) 3.4% (263) 1.7 (0.6, 5.4) 0.32
Wisconsin Sleep Cohort 15.4% (421) 5.8% (2114) 3.0 (2.1, 4.1) ,0.0001
All samples 13.6% (530) 5.6% (2457) 2.7 (2.0, 3.6) ,0.0001
Results are presented as percentages of positive anti-PDI sera (number of all sera in this subgroup).
$ASLO positivity defined as ASLO $200 for participants ages 6–40 years and ASLO $100 for participants older than 40 years, as recommended [40].
"Anti-bovine PDI defined as positive if ELISA OD $0.5.
#Anti-human PDI defined as positive if ELISA OD $0.75.
doi:10.1371/journal.pone.0012875.t001
Figure 2. Mimicry between PDI and Streptolysin O (SLO). (A) Competitive ELISA demonstrates a common SLO-PDI determinant. Serum
samples (n=20) positive for anti-PDI, anti-Helicobacter Pillory (HP) and anti-cardiolipin (ACL) antibodies were pre-incubated with increasing amounts
of SLO (0–32 ng/ml) and subjected to ELISAs (PDI, HP and ACL). Baselines (100%) were determined by incubation of each serum with PBS only. Results
are presented as a mean 6 SEM. (B) Reactivity of ASLO antibodies with and without anti-PDI activity. Purified bovine PDI (100 ng) and purified SLO
(10 ng) were subjected to SDS gel electrophoresis followed by immunoblotting with Affinity purified anti-SLO antibodies from anti-PDI positive (left)
– and anti-PDI negative (right) subjects. (C) Similar immunogenic determinants in SLO and PDI. The 11 amino-acids sequence of the similar
determinant is presented in SLO (p51–p61), bovine/rat PDI – (p330-340) and human PDI (p328-338). (D) Location of the similar determinant on the
PDI protein (in yellow, pointed by an arrow). Left – structure of all 4 subunits (yeast). Right – focus on the b’ subunit (human), an important subunit
containing the substrate binding site. Note that the similar determinant is in the exposed area of the binding site. In the SLO protein, the determinant
is also exposed (p51-61; not shown).
doi:10.1371/journal.pone.0012875.g002
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bovine PDI were used. Purified anti-PDI antibodies and diluted
sera positive for anti-human and/or anti-bovine PDI strongly
inhibited PDI activity (Figure 3 and Fig. S2 B).
Anti-PDI antibodies are associated with higher serum
insulin and insulin resistance
Links between infections, immunity, obesity, and metabolic
syndrome were recently described [26,27]. We hypothesized
that the identified anti-PDI antibodies may, at least partially,
underlie this association. We tested this hypothesis using samples
from the Wisconsin Sleep Cohort, an ongoing longitudinal study
of sleep and metabolic indices in Wisconsin state employees
[28]. We compared serum insulin and fasting glucose levels in
participants with and without anti-human PDI (n=1215). As
hypothesized, participants who were positive for anti-human
PDI had significantly higher insulin levels and higher HOMA
(Homeostatic Model Assessment of insulin resistance; HOMA
= insulin x Glucose/405), compared to anti-human PDI
negative subjects. The results were adjusted for age, gender,
education, BMI, and smoking (Figure 3, Table S2). Sleep
Disordered Breathing (Apnea-Hypopnea Index) had no effect on
the association.
In samples of the same participant tested 4 years apart, the anti
PDI positivity for successive visits was correlated (Kappa=0.32,
95% CI: 0.22, 0.42, p,0.0001, n=1118 subjects with $2 visits),
with 33% of samples positive at baseline remaining positive 4 years
later, suggesting moderately long stability for this autoantibody
(years but not decades).
Discussion
SLO is a highly immunogenic streptococcal toxin that induces
ASLO antibodies in a majority of subjects following streptococcal
pharyngitis, hence its clinical utility as a marker. Titers typically
increase after 2 weeks, peak at 2–4 months, and decrease
thereafter [29]. In most cases, these antibodies do not target the
SLO-p51-61 epitope, which we identified to be homologous to
PDI- p328-338, an epitope located within the PDI binding site and
crucial to its function. In about 8% of the general population,
however, molecular mimicry with human PDI occurs (Table 1),
with functional effects on the enzyme activity (Figure 3).
Importantly, the human serum dilution used in the enzyme
inhibition studies (1:50, similar to that used in the ELISA assays) is
compatible with physiological effects in vivo.
The higher affinity of the human anti-SLO-p51-61 antibodies to
the bovine/rat antigens (which share higher homology to SLO than
Figure 3. Functional effect of anti-PDI antibodies on PDI activity and association of anti-PDI status with insulin resistance. (A) Effects
of purified anti-PDI antibodies on purified bovine PDI activity. Purified Bovine PDI activity was measured in the presence of 0–60 mg/ml purified anti-
bovine PDI from anti-PDI positive subjects (triangles) and 0–160 mg/ml total IgG from rabbit immuned against bovine PDI (diamonds). Pooled human
and rabbit IgG (dashed lines) were used as control. Results are compared to activity in the presence of same volume of PBS (defined as 100%) and
presented as a mean 6 SEM of three experiments. PDI activity was measured using the insulin transhydrogenase assay. (B) Effects of human sera
(1:50) on human recombinant PDI activity. Recombinant human PDI activity was measured in the presence of 20 ml/ml human sera positive or
negative for anti-human PDI antibody. Results are presented as mean 6 SEM. (C) Association of anti- human PDI status with serum insulin levels.
Results are presented as mean 6 SEM, adjusted for age, gender, education, BMI and smoking. (D) Association of anti-human PDI status with insulin
resistance. Insulin resistance was estimated using HOMA (Homeostatic Model Assessment of insulin resistance). Results are presented as mean 6
SEM, adjusted for age, gender, education, BMI and smoking. For details, see Table S2.
doi:10.1371/journal.pone.0012875.g003
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was a bridge to the identification of the anti-human PDI.
Here we suggest, for the first time, that beta hemolytic
streptococcal infections may contribute in some cases to insulin
resistance. Although the presence of an autoantibody does not
necessarily mean an autoimmune disease, the functional charac-
teristics of anti-PDI combined with the epidemiological associa-
tions with altered insulin metabolism suggest an autoimmune
contribution to the pathogenesis of insulin resistance. A possible
pathway is reduced insulin degradation by the anti-PDI, that leads
to higher insulin and eventually insulin resistance [30] (Figure 4).
We used the homeostatic model assessment (HOMA) to assess
insulin resistance. While HOMA has been validated against a
variety of physiological methods and its use in cohort and
epidemiological studies is considered appropriate, it is not a
definitive measurement of insulin resistance and should be
interpreted cautiously [31]. In our study an average HOMA of
3.1wasfoundinparticipantswithout anti-PDI antibodiescompared
to 4.1 (33% higher) in participants positive for this autoantibody. As
cutoff of 3.6 to 4.6 has been suggested for the diagnosis of insulin
resistance (depends on the BMI of the tested individual) [32], this
HOMA difference between the groups is probably of clinical
significance. Nevertheless, the use of definitive techniques for the
measurement of insulin resistance should be considered in future
studies including the euglycemic insulin clamp technique, the
glucose tolerance test and the insulin suppression test.
Multiple genetic and environmental factors are probably
involved in the pathogenesis of insulin resistance. This study
suggests that one of these genetic-environmental combinations is
the tendency to produce and maintain anti-PDI antibodies
following Streptococcal infection. Further studies are needed to
explore the associations between anti-PDI antibodies, HLA (and
other genetic markers using genome wide association), family
history of type 2 diabetes, and Insulin resistance.
As PDI is a pleiotropic enzyme, additional effects of this
functional autoantibody are likely. Most notably, extracellular PDI
is now recognized as a key player in platelet activation and fibrin
formation [14,15,16,17,18]. In-vitro and in-vivo studies have shown
functional effects of experimentally induced anti-PDI antibodies
on platelet activation mediated by the platelet Fc receptor [33],
and fibrin formation[17]. Extracellular PDI is also involved in
resistance to infection [12,13], cardiovascular disease [19,34], and
immune recognition of cancer [35,36,37]. Our findings broaden
the spectrum of post-streptococcal immunity and suggest effects on
insulin metabolism. Further clinical studies, encompassing also
other areas of medicine where PDI has a role, are clearly needed
to determine the full clinical impact of this novel autoantibody.
Methods
Ethics Statement
The Study was approved by the institutional review boards of
Stanford and Wisconsin Universities, and a written informed
consent was obtained from all participants. Animal studies were
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol was approved by the
Institutional Animal Care and Use Committee (IACUC)of
Stanford University (Permit Number:13985).
Subjects
Stanford cohorts included 310 and 372 healthy volunteers
(mean age 25.9611.8 years (range 3.4–86 years), 58% females).
The Wisconsin Sleep Cohort [28] is an ongoing longitudinal study.
Metabolic and sleep data, and blood samples are obtained from
each participant every four years (2,847 visits/serum samples in
1211 participants). Mean age at blood draw 55.568.6 years (range
33.1–74.5); 45.5% females.
Antibodies, Reagents, and Commercially available Assays
Proteins and Antigens: bovine PDI, Streptolysin O, and bovine
insulin were obtained from Sigma-Aldrich; PDI recombinant
Figure 4. Possible pathway mediating insulin resistance in subjects with post-streptococcal anti-PDI autoantibodies. Streptococcal
infections induce production of anti-Streptolysin O antibodies (ASLO), some of which share a common determinant with PDI. Molecular mimicry leads
to inhibition of PDI which among other functions reduces and degrades insulin. The disulfide bonds of insulin are generated on the preproinsulin
peptide, and thus reduction of any of the two disulfide bonds of insulin results in irreversible changes in activity. We hypothesize that lower
degradation of insulin by PDI in the presence of anti-PDI antibodies result in higher insulin levels and insulin resistance.
doi:10.1371/journal.pone.0012875.g004
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designed for this study - from GenScript. Antibodies: Rabbit
polyclonal anti-bovine PDI, human IgG, and rabbit IgG from
Sigma-Aldrich; Donkey anti-human IgG conjugated with horse-
radish peroxidase - from Jackson ImmunoResearch Laboratories.
Assays: Insulin - from Linco Research; ASLO – SeraTest ASO,
Remel; ADB - Streptonase-B, Wampole Laboratories; Anti-
Helicobacter Pylori IgG ELISA - H. pylori IgG BioCheck; Anti-
cardiolipin IgG ELISA - Cardiolipin IgG ELISA, Calbiotech.
Other kits: Reversible protein detection kit - Sigma-Aldrich;
Montage Antibody Purification Kit with PROSEP-G media-
Millipore; Chemiluminescence ECL kit - Thermo scientific;
Tetramethylbenzidine (TMB) kit- Vector Laboratories.
Western Analyses
Tissue collected from Wistar rats were homogenized in RIPA
buffer, and centrifuged (17,0006 g; 20 min, 10uC). The
supernatant was denatured (85uC, 5 min), electrophoresed (10%
acrylamide gel), and transferred to 0.45-mm nitrocellulose (100V,
80 min). Fifteen to 30 mg tissue extract (or 1 mg purified protein)
were loaded in each lane. Membranes were stained reversibly
stained (kit) to confirm homogeneity of protein loading, and cut in
separate strips. Strips were blocked (5% milk in PBS; 90 minutes),
and incubated with individual human sera (diluted 1:250–500) or
total IgG (purified from serum using Montage Antibody
Purification Kit; 10 m/ml; 120 minutes, room temp), and then
with secondary antibody (Donkey anti-human IgG -HRP,
1:25,000). Immunoreactive proteins were visualized using ECL
kit according to the manufacturer’s instructions.
Isoelectric focusing/SDS-PAGE two-dimensional
electrophoresis (2-DE)
Isoelectric focusing (IEF) buffer was prepared with 2% (volume/
volume) ampholyte (pH 3.7–9.2). Rat tissue extracts (2.5 mg,
prepared in IEF lysis buffer) were dissolved in a final IEF buffer
volume of 2.5 ml, applied to MicroRotofor (Bio-Rad), and
electrophoresed for 1.5–2.5 hours (1W constant power, 4uC).
Protein fractions (106200 ı `l) were harvested, and submitted to
SDS-PAGE (12% or 15% polyacrylamide).
Extraction of Streptococcus pyogenes antigens
S. pyogenes was grown in Todd-Hewitt broth (18 hrs, 37uC)
without agitation. Extracellular (CS) antigens were obtained by
precipitation of culture supernatant (1500 ml) with 80% saturated
(NH4)2SO4. After centrifugation (110006g, 60 min, 10uC),
proteins were suspended in 6 ml PBS or IEF buffer, dialyzed
(4uC overnight against dH2O), and filter sterilized.
Mass Spectrometry identification of immunoreactive
bands
Following IEF and SDS–PAGE, gels were stained (GelCode
Blue, PIERCE), target bands excised, and subjected to tryptic
digestion according to the instructions of the UCSF Mass
Spectrometry Core facility (http://donatello.ucsf.edu/ingel.html).
Tryptic fragments were analyzed by mass spectrometry (MALDI-
TOF system,Voyager DE-PRO, Applied Biosystems, BMSF,
UNSW). MOWSE probability score, sequence coverage, pI, and
molecular weight values were used to identify the most likely
candidate protein for each band.
Anti-PDI determination using ELISA
Microtiter plates (96 wells) were coated with bovine (100 mlo f
1.5 mg/mL) or recombinant human (100 mlo f5 mg/mL) PDI
(incubated at 4uC, 24 hours). Plates were rinsed and flicked 3x,
blocked (5% milk), and exposed to human diluted sera (90 min,
room temperature). Anti-bovine PDI antibodies were detected
using a 1:250 dilution; anti-human PDI antibodies using a 1:50
dilution. Donkey anti-human IgG-HRP (1:10,000 ) was used as the
secondary antibody. To detect antibody–antigen interactions
tetramethylbenzidine (TMB) was added (reaction stopped at
5 min with 50 ml H3PO4 (1M)), and the resulting signal read at
450 nm (Molecular Devices EMAX micro plate reader). The
cutoff for positive was OD $0.5 for anti-bovine PDI and
OD$0.75 for anti-human PDI (due to higher background). All
samples were assayed in duplicate.
Affinity purification of anti-PDI and ASLO Antibodies
Total IgG from anti-bovine PDI positive and/or ASLO positive
sera were affinity-purified using bovine PDI (Affinity Life Sciences,
Inc) or SLO (AminoLink Plus Immobilization Kit, Thermo
Scientific).
Insulin transhydrogenase assays
Bovine insulin (250 mg) was suspended in 250 ml of TRIS
50 mM, EDTA 2 mM, PH-7.5. Bovine or recombinant human
PDI (0.5 mg) was added, and reaction initiated with 1 ml of 0.1M
DTT (dithiothreitol). The transhydrognation of insulin was
monitored by absorbance (OD650nm) over a 70 minute period.
Inhibitors of PDI -mediated insulin transhydrogenation were pre-
incubated with PDI and insulin for 45 minutes prior to the
addition of DTT.
Epitope modeling
Several models for the structure of SLO and the yet unresolved
fragments of PDI were generated using modeller [38] and I-
TASSER [39] These models were manually refined prior to
analysis for a common structural determinant.
Statistical analysis
Unless otherwise specified, data is presented as mean 6 SD.
Group comparisons were primarily made using Pearson’s x
2 or
Student’s t-tests. In selected cases, multivariate analyses were used
to control for possible covariates of interest. Finally, in studies of
the Wisconsin cohort, glucose metabolic variables were compared
on repeated observations using weighted average, with control of
known confounders (Table S2). The statistical packages SYSTAT
or SAS were used for these analyses.
Supporting Information
Figure S1 PDI regulates polypeptides structure and function. (A)
The reduced amino acid cysteine has a sulphur atom (S), as a thiol
group (SH). (B) Disulfide bonds (bridge) are covalent bonds formed
between two sulfur atoms across two cysteine residues on a protein
or polypeptide, which stabilizes the protein/polypeptide tertiary
structure. (C) Oxidized PDI binds proteins with thiol groups (C1)
and uses its own disulfide bond to oxidize thiols on the target
protein, forming a disulfide bridge (C2). The resulting structural
change can activate/deactivate target proteins. Reduced PDI
binds proteins with disulfide bridges (C2) and can either reduce
them to thiols (C1) or change the disulfide bridges (C3), thus
altering the protein structure.
Found at: doi:10.1371/journal.pone.0012875.s001 (1.34 MB TIF)
Figure S2 Heterogeneity of epitopes in anti-human PDI
autoantibodies, and impact on PDI inhibition. (A) Serum samples,
positive for anti-bovine PDI, anti-human PDI, or both, were
Post-Streptococcal Anti-PDI
PLoS ONE | www.plosone.org 6 September 2010 | Volume 5 | Issue 9 | e12875pre-incubated with: 1) PBS; 2) synthetic peptide of the human PDI
11 amino acids determinant -p328-338 (Figure 2C, 100 ng/ml); 3)
synthetic peptide of the bovine PDI 11 amino acids determinant-
p330-340 (Figure 2C, 100 ng/ml). Treated sera were subjected to
anti-bovine PDI ELISA (left) and to anti-human PDI ELISA
(right). Results are presented as mean 6SEM of 3 experiments.
Rabbit induced anti-PDI was used as positive control. The results
suggest at least two types of anti-human PDI determinants. One
targets the 11aa determinant similar in PDI and SLO (targets both
human and bovine PDI and inhibited by both determinants). The
other type(s) (human-PDI specific only) target a different
determinant on the human-PDI protein and are not inhibited by
the PDI-SLO 11 aa similar determinant (as the rabbit serum anti-
PDI control). (B) Impact of anti-human PDI antibodies on
recombinant human PDI activity, as measured by the insulin
transhydrogenase assay (see Figure 3). The activity was measured
when PBS was added to the reaction mix (defined as 100%
activity) versus sera (20 ml/ml ) was added. Sera positive for both
anti human and anti bovine PDI (right bar) are contrasted with
sera positive for anti-human PDI only (middle) and with sera
negative for anti-human PDI and anti-bovine PDI (left). Results
are presented as mean 6 SEM. Human PDI inhibition by sera
positive for both antibodies was stronger compared to inhibition
by sera positive for anti-human PDI only (P,0.001).
Found at: doi:10.1371/journal.pone.0012875.s002 (0.58 MB TIF)
Table S1 Characteristics of participants positive for anti-human
and bovine PDI antibodies. Data is presented as number (%) of
studies or as mean (SEM) for age. #: Adjusted with ASO status;
* Caucasians vs. all other ethnic groups.
Found at: doi:10.1371/journal.pone.0012875.s003 (0.06 MB
PDF)
Table S2 Serum insulin, glucose and HOMA by anti-human
PDI status. Data is presented as mean (SEM) or as N-number of
studies (%). * Adjusted for age, BMI, gender, smoking and
education. HOMA - Homeostatic Model Assessment of insulin
resistance. Note: A higher value indicates increased resistance.
Found at: doi:10.1371/journal.pone.0012875.s004 (0.04 MB
PDF)
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